Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
Abstract Background Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of pla...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | Translational Neurodegeneration |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40035-023-00365-x |
| _version_ | 1797789600290177024 |
|---|---|
| author | Jiaying Lu Xiaoxi Ma Huiwei Zhang Zhenxu Xiao Ming Li Jie Wu Zizhao Ju Li Chen Li Zheng Jingjie Ge Xiaoniu Liang Weiqi Bao Ping Wu Ding Ding Tzu-Chen Yen Yihui Guan Chuantao Zuo Qianhua Zhao on behalf of the Shanghai Memory Study (SMS) |
| author_facet | Jiaying Lu Xiaoxi Ma Huiwei Zhang Zhenxu Xiao Ming Li Jie Wu Zizhao Ju Li Chen Li Zheng Jingjie Ge Xiaoniu Liang Weiqi Bao Ping Wu Ding Ding Tzu-Chen Yen Yihui Guan Chuantao Zuo Qianhua Zhao on behalf of the Shanghai Memory Study (SMS) |
| author_sort | Jiaying Lu |
| collection | DOAJ |
| description | Abstract Background Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and positron emission tomography (PET) ATN biomarkers in subjects with cognitive complaints. Methods A hospital-based cohort of subjects with cognitive complaints with a concurrent blood draw and ATN PET imaging (18F-florbetapir for A, 18F-Florzolotau for T, and 18F-fluorodeoxyglucose [18F-FDG] for N) was enrolled (n = 137). The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances. Results Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort. Plasma p-tau181 level and PET standardized uptake value ratios of AT biomarkers showed a similarly excellent diagnostic performance for distinguishing between Aβ+ and Aβ− subjects. An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects. Additionally, glucose hypometabolism – along with elevated plasma neurofilament light chain level – was related to more severe cognitive impairment in Aβ− subjects. Conclusion Plasma p-tau181, as well as 18F-florbetapir and 18F-Florzolotau PET imaging can be considered as interchangeable biomarkers in the assessment of Aβ status in symptomatic stages of AD. 18F-Florzolotau and 18F-FDG PET imaging could serve as biomarkers for the severity of cognitive impairment. Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use. |
| first_indexed | 2024-03-13T01:52:59Z |
| format | Article |
| id | doaj.art-e367ba73f71f46cebe83a33a0d20faf3 |
| institution | Directory Open Access Journal |
| issn | 2047-9158 |
| language | English |
| last_indexed | 2024-03-13T01:52:59Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Translational Neurodegeneration |
| spelling | doaj.art-e367ba73f71f46cebe83a33a0d20faf32023-07-02T11:25:24ZengBMCTranslational Neurodegeneration2047-91582023-06-0112111510.1186/s40035-023-00365-xHead-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaintsJiaying Lu0Xiaoxi Ma1Huiwei Zhang2Zhenxu Xiao3Ming Li4Jie Wu5Zizhao Ju6Li Chen7Li Zheng8Jingjie Ge9Xiaoniu Liang10Weiqi Bao11Ping Wu12Ding Ding13Tzu-Chen Yen14Yihui Guan15Chuantao Zuo16Qianhua Zhao17on behalf of the Shanghai Memory Study (SMS)Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityNational Clinical Research Center for Aging and Medicine and National Center for Neurological Disorders, Huashan Hospital, Fudan UniversityDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityNational Clinical Research Center for Aging and Medicine and National Center for Neurological Disorders, Huashan Hospital, Fudan UniversityDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityNational Clinical Research Center for Aging and Medicine and National Center for Neurological Disorders, Huashan Hospital, Fudan UniversityDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityDepartment of Ultrasound, Huashan Hospital, Fudan UniversityNational Clinical Research Center for Aging and Medicine and National Center for Neurological Disorders, Huashan Hospital, Fudan UniversityDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityNational Clinical Research Center for Aging and Medicine and National Center for Neurological Disorders, Huashan Hospital, Fudan UniversityDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityNational Clinical Research Center for Aging and Medicine and National Center for Neurological Disorders, Huashan Hospital, Fudan UniversityAPRINOIA Therapeutics Co., LtdDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityDepartment of Nuclear Medicine and PET Center, Huashan Hospital, Fudan UniversityNational Clinical Research Center for Aging and Medicine and National Center for Neurological Disorders, Huashan Hospital, Fudan UniversityAbstract Background Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and positron emission tomography (PET) ATN biomarkers in subjects with cognitive complaints. Methods A hospital-based cohort of subjects with cognitive complaints with a concurrent blood draw and ATN PET imaging (18F-florbetapir for A, 18F-Florzolotau for T, and 18F-fluorodeoxyglucose [18F-FDG] for N) was enrolled (n = 137). The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances. Results Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort. Plasma p-tau181 level and PET standardized uptake value ratios of AT biomarkers showed a similarly excellent diagnostic performance for distinguishing between Aβ+ and Aβ− subjects. An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects. Additionally, glucose hypometabolism – along with elevated plasma neurofilament light chain level – was related to more severe cognitive impairment in Aβ− subjects. Conclusion Plasma p-tau181, as well as 18F-florbetapir and 18F-Florzolotau PET imaging can be considered as interchangeable biomarkers in the assessment of Aβ status in symptomatic stages of AD. 18F-Florzolotau and 18F-FDG PET imaging could serve as biomarkers for the severity of cognitive impairment. Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use.https://doi.org/10.1186/s40035-023-00365-xATN biomarkersPET imagingPlasmaClinical severity |
| spellingShingle | Jiaying Lu Xiaoxi Ma Huiwei Zhang Zhenxu Xiao Ming Li Jie Wu Zizhao Ju Li Chen Li Zheng Jingjie Ge Xiaoniu Liang Weiqi Bao Ping Wu Ding Ding Tzu-Chen Yen Yihui Guan Chuantao Zuo Qianhua Zhao on behalf of the Shanghai Memory Study (SMS) Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints Translational Neurodegeneration ATN biomarkers PET imaging Plasma Clinical severity |
| title | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
| title_full | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
| title_fullStr | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
| title_full_unstemmed | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
| title_short | Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints |
| title_sort | head to head comparison of plasma and pet imaging atn markers in subjects with cognitive complaints |
| topic | ATN biomarkers PET imaging Plasma Clinical severity |
| url | https://doi.org/10.1186/s40035-023-00365-x |
| work_keys_str_mv | AT jiayinglu headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT xiaoxima headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT huiweizhang headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT zhenxuxiao headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT mingli headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT jiewu headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT zizhaoju headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT lichen headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT lizheng headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT jingjiege headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT xiaoniuliang headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT weiqibao headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT pingwu headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT dingding headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT tzuchenyen headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT yihuiguan headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT chuantaozuo headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT qianhuazhao headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints AT onbehalfoftheshanghaimemorystudysms headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints |